2024-07-22 02:12:14
THPharm, a company specializing in metabolic disease treatment, announced on the 18th that it signed a business agreement (MOU) with Dt&CRO for the development of an oral GLP-1 obesity treatment.
The oral GLP-1-containing obesity treatment drug developed by TH Pharm through this agreement has the advantage of a new administration method that differentiates it from existing injectable GLP-1 obesity treatments such as Saxenda, Wigobi, and Zebbound. GLP-1 is a hormone secreted in the small intestine when food is consumed, and it shows the effects of regulating blood sugar and reducing appetite by promoting insulin secretion and suppressing glucagon secretion. Existing injectable GLP-1 obesity treatments had disadvantages such as fear of injections, pain, and discomfort, but TH Pharm’s oral formulation can increase medication compliance and expect continuous therapeutic effects.
TEHPharm is a company specializing in the development of new oral improved drugs and new drugs related to metabolic diseases. In particular, it plans to accelerate product development to improve medication compliance and maximize efficacy by utilizing technology to study dosage forms suitable for administration according to indications.
Based on its expertise in the field of non-clinical-clinical trials and evaluations of pharmaceuticals, DTNCRO plans to actively support TH Pharm’s development of an oral GLP-1 obesity treatment. In particular, it plans to maximize the efficacy and benefits of the treatment through targeted non-clinical-clinical design design and trial implementation.
A TH Pharm official said, “We expect that this agreement will speed up the development of GLP-1 obesity treatment and advance our market entry,” adding, “We will accelerate our lead in the obesity treatment market with a new oral formulation that improves patient convenience.”
Reporter Yong-Seok Choi, Donga.com [email protected]
-
- great
- 0dog
-
- I’m so sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news right now
2024-07-22 02:12:14